Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $249.0 million.

  • Heron Therapeutics' Liabilities and Shareholders Equity rose 1276.08% to $249.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $949.9 million, marking a year-over-year increase of 803.28%. This contributed to the annual value of $233.1 million for FY2024, which is 478.23% up from last year.
  • Heron Therapeutics' Liabilities and Shareholders Equity amounted to $249.0 million in Q3 2025, which was up 1276.08% from $232.1 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Liabilities and Shareholders Equity registered a high of $404.2 million during Q2 2021, and its lowest value of $201.2 million during Q2 2023.
  • In the last 5 years, Heron Therapeutics' Liabilities and Shareholders Equity had a median value of $235.8 million in 2025 and averaged $257.6 million.
  • Per our database at Business Quant, Heron Therapeutics' Liabilities and Shareholders Equity tumbled by 3965.0% in 2022 and then soared by 1276.08% in 2025.
  • Heron Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $305.7 million in 2021, then decreased by 17.91% to $251.0 million in 2022, then decreased by 11.33% to $222.5 million in 2023, then rose by 4.78% to $233.1 million in 2024, then grew by 6.78% to $249.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $249.0 million in Q3 2025, compared to $232.1 million in Q2 2025 and $235.8 million in Q1 2025.